Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International

Jaguar Health, Inc., a commercial stage pharmaceutical company, has officially appointed Dr. Massimo Radaelli as President of Jaguar International. Announced on April 2, 2024, Dr. Radaelli, with over 35 years of experience in the biopharmaceutical sector focusing on rare diseases and innovation in therapies, is expected to enhance Jaguar's commercial presence outside the U.S.

Dr. Radaelli played a pivotal role in a recent out-license agreement with GEN, a Turkish pharmaceutical company, to commercialize crofelemer in Turkey and eight neighboring countries. This deal also involves a $2.0 million investment in Jaguar stock at a premium price. Lisa Conte, Jaguar's president and CEO, expressed confidence in Dr. Radaelli's expertise in pharmacology, clinical research, business development, and international commercialization to further Jaguar's international business strategy.

Dr. Radaelli's approach focuses on expanding access to prescription pharmaceuticals for essential supportive care and management of neglected symptoms associated with complex diseases. His aim is to utilize his vast experience to further Jaguar's mission in therapeutic sectors of orphan drugs, rare diseases, and supportive care by extending the company's international footprint through partnerships and direct market presence.

Previously honored as Commander of the Italian Republic for Special Merits, Dr. Radaelli has been recognized for his contributions to science and the biopharmaceutical industry, particularly in rare and neglected diseases. This high-ranking honor highlights Dr. Radaelli's significant impact and dedication in his field.